MX2017013049A - Formas de sal farmaceuticas de un inhibidor de amina oxidasa sensible a semicarbazida (ssao). - Google Patents

Formas de sal farmaceuticas de un inhibidor de amina oxidasa sensible a semicarbazida (ssao).

Info

Publication number
MX2017013049A
MX2017013049A MX2017013049A MX2017013049A MX2017013049A MX 2017013049 A MX2017013049 A MX 2017013049A MX 2017013049 A MX2017013049 A MX 2017013049A MX 2017013049 A MX2017013049 A MX 2017013049A MX 2017013049 A MX2017013049 A MX 2017013049A
Authority
MX
Mexico
Prior art keywords
ssao
semicarbazide
inhibitor
salt forms
pharmaceutical salt
Prior art date
Application number
MX2017013049A
Other languages
English (en)
Spanish (es)
Inventor
Savory Edward
Higginbottom Michael
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of MX2017013049A publication Critical patent/MX2017013049A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2017013049A 2015-04-24 2016-04-22 Formas de sal farmaceuticas de un inhibidor de amina oxidasa sensible a semicarbazida (ssao). MX2017013049A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1507031.1A GB201507031D0 (en) 2015-04-24 2015-04-24 New pharmaceutical salt forms
PCT/GB2016/051119 WO2016170351A1 (en) 2015-04-24 2016-04-22 Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao)

Publications (1)

Publication Number Publication Date
MX2017013049A true MX2017013049A (es) 2017-12-08

Family

ID=53488629

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013049A MX2017013049A (es) 2015-04-24 2016-04-22 Formas de sal farmaceuticas de un inhibidor de amina oxidasa sensible a semicarbazida (ssao).

Country Status (19)

Country Link
US (1) US10316034B2 (cg-RX-API-DMAC7.html)
EP (1) EP3286190B1 (cg-RX-API-DMAC7.html)
JP (2) JP2018513189A (cg-RX-API-DMAC7.html)
KR (1) KR20170139045A (cg-RX-API-DMAC7.html)
CN (2) CN107531702A (cg-RX-API-DMAC7.html)
AR (1) AR104360A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016251707B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017020016A2 (cg-RX-API-DMAC7.html)
CA (1) CA2979144A1 (cg-RX-API-DMAC7.html)
DK (1) DK3286190T3 (cg-RX-API-DMAC7.html)
EA (1) EA035668B1 (cg-RX-API-DMAC7.html)
ES (1) ES2804155T3 (cg-RX-API-DMAC7.html)
GB (1) GB201507031D0 (cg-RX-API-DMAC7.html)
HU (1) HUE049985T2 (cg-RX-API-DMAC7.html)
IL (1) IL254153A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017013049A (cg-RX-API-DMAC7.html)
PT (1) PT3286190T (cg-RX-API-DMAC7.html)
SG (1) SG11201707867WA (cg-RX-API-DMAC7.html)
WO (1) WO2016170351A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain
GB201618029D0 (en) 2016-10-25 2016-12-07 Proximagen Ltd New process
CN108017634A (zh) * 2017-12-15 2018-05-11 清华大学 一种制备吡咯并多环衍生物的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141899A (en) 1976-01-07 1979-02-27 Societa' Farmaceutici Italia S.P.A. 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
IT1098015B (it) 1978-08-07 1985-08-31 Farmaceutici Italia Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU3956900A (en) * 1999-04-16 2000-11-02 Boehringer Ingelheim International Gmbh Substituted imidazoles, their preparation and use
WO2002038153A1 (en) * 2000-11-09 2002-05-16 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
SE0004101D0 (sv) 2000-11-09 2000-11-09 Pharmacia Ab New use
EP1732531A2 (en) * 2004-02-25 2006-12-20 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
US20070066646A1 (en) 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
WO2007146188A2 (en) 2006-06-07 2007-12-21 The Board Of Trustees Of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
JP5539989B2 (ja) * 2008-09-16 2014-07-02 プロキシマジェン エルティーディー 新規化合物ｉ
US8633318B2 (en) * 2008-09-16 2014-01-21 Proximagen Ltd Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
CN103889983B (zh) * 2011-09-14 2015-12-09 普罗克西梅根有限公司 酶抑制剂化合物
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
AU2014279863A1 (en) 2013-06-12 2016-01-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
ES2714125T3 (es) 2014-04-15 2019-05-27 Pecsi Tudomanyegyetem Inhibidores de la amino oxidasa sensible a la semicarbazida para uso como analgésicos en una neuropatía traumática y una inflamación neurogénica
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound

Also Published As

Publication number Publication date
JP2018513189A (ja) 2018-05-24
AR104360A1 (es) 2017-07-12
WO2016170351A1 (en) 2016-10-27
IL254153A0 (en) 2017-10-31
HK1249906A1 (en) 2018-11-16
AU2016251707A1 (en) 2017-10-05
CN112851669A (zh) 2021-05-28
US20180111928A1 (en) 2018-04-26
DK3286190T3 (da) 2020-07-13
EA035668B1 (ru) 2020-07-23
SG11201707867WA (en) 2017-11-29
CA2979144A1 (en) 2016-10-27
EP3286190B1 (en) 2020-06-03
ES2804155T3 (es) 2021-02-04
HUE049985T2 (hu) 2020-11-30
US10316034B2 (en) 2019-06-11
EP3286190A1 (en) 2018-02-28
JP2021073256A (ja) 2021-05-13
GB201507031D0 (en) 2015-06-10
KR20170139045A (ko) 2017-12-18
AU2016251707B2 (en) 2020-02-20
BR112017020016A2 (pt) 2018-06-19
EA201792121A1 (ru) 2018-03-30
CN107531702A (zh) 2018-01-02
PT3286190T (pt) 2020-07-09

Similar Documents

Publication Publication Date Title
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
MX378273B (es) Compuestos activos hacia bromodominios.
NZ733174A (en) Quinazoline derivatives used to treat hiv
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
SI3805233T1 (sl) (r)in (s) enantiomera n-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo(4,5-b)piridin-6-il) -2-(2-metilpiridin-4-il)oksazol-karboksamid kot inhibitorji irak4 za zdravljenje raka
MX381994B (es) Inhibidor de janus quinasa.
IN2014DN10670A (cg-RX-API-DMAC7.html)
PH12016500170A1 (en) Formulation of syk inhibitors
TW201613864A (en) Novel compounds
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
WO2014153495A3 (en) Novel stat3 inhibitors
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX2020001875A (es) Forma polimorfica de tg02.
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2017013047A (es) Tratamiento de dolor.
MX2017013049A (es) Formas de sal farmaceuticas de un inhibidor de amina oxidasa sensible a semicarbazida (ssao).
JOP20170115B1 (ar) مشتقات بيريدينيل، تركيبات صيدلية منها واستخداماتها كمثبطات aoc3
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
SI3778609T1 (sl) Derivati penama ali njenih soli, farmacevtski sestavki in njihova uporaba
EA033064B1 (ru) Кристаллическое соединение как ингибитор фермента семикарбазидчувствительной аминоксидазы (ssao)
MX387920B (es) Peptidos antagonistas de prgc.
MX389403B (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo